|
Patent landscape, scope, and claims: |
Patent 7,173,037: Analysis of Scope, Claims, and Landscape for Xyrem
Patent US 7,173,037 B2, titled "Pharmaceutical compositions containing gamma-hydroxybutyrate and methods of treatment," describes and claims pharmaceutical compositions and methods of treatment utilizing gamma-hydroxybutyrate (GHB). The patent is assigned to Jazz Pharmaceuticals, Inc.
What is the Core Technology Protected by Patent 7,173,037?
The patent protects pharmaceutical compositions containing GHB, specifically in a form intended for therapeutic administration. It also covers methods for treating conditions utilizing these compositions.
What are the Key Ingredients and Formulations Claimed?
Claim 1 of US 7,173,037 defines a pharmaceutical composition comprising:
- Gamma-hydroxybutyrate (GHB): This is the active pharmaceutical ingredient. The patent specifies various salts of GHB, including sodium, potassium, calcium, and magnesium.
- A buffering agent: This component is included to maintain the pH of the composition within a specific range, thereby enhancing stability and potentially improving palatability or absorption. The patent lists examples such as citrate, phosphate, and acetate buffering systems.
- A pharmaceutically acceptable carrier: This is a substance that carries the active ingredient and buffering agent, enabling its administration. Examples provided include water, sorbitol, and various glycols.
The claimed compositions are intended for oral administration and are designed to deliver GHB in a controlled and stable manner.
What are the Specific Therapeutic Methods Claimed?
The patent claims methods for treating various conditions using the aforementioned pharmaceutical compositions. Primarily, the focus is on the treatment of:
- Idiopathic Hypersomnia: A rare neurological sleep disorder characterized by excessive daytime sleepiness.
- Narcolepsy: A chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, leading to uncontrolled daytime sleepiness.
The methods involve administering a therapeutically effective amount of the claimed GHB composition to a patient in need thereof. The patent specifies dosages and administration schedules relevant to these conditions.
What is the Legal Scope and Claimed Exclusivity?
The patent's claims define the boundaries of the intellectual property protection. US 7,173,037 has independent and dependent claims that broaden or narrow the scope of protection.
What are the Independent Claims and Their Breadth?
The most significant independent claims are typically those that define the core composition and method.
- Claim 1 (Composition): As detailed above, this claim defines a specific combination of GHB, a buffering agent, and a pharmaceutically acceptable carrier. The presence of these three components in combination is central to its protection.
- Claim 15 (Method of Treatment): This independent method claim broadly covers the "method of treating idiopathic hypersomnia or narcolepsy in a patient, comprising administering to the patient a pharmaceutical composition of claim 1." This links the method of treatment directly to the specific composition claimed.
The scope of these claims is generally interpreted to cover compositions that embody all the limitations recited in the claims. Variations that do not include all elements or substantially differ in their essential elements may fall outside the patent's protection.
How do Dependent Claims Refine the Protection?
Dependent claims typically add further limitations to the independent claims, narrowing the scope but potentially strengthening enforceability. Examples of limitations found in dependent claims within US 7,173,037 include:
- Specific GHB salts: Claims may specify sodium GHB or other particular salt forms.
- Specific buffering agents: Further claims might identify citrate or phosphate buffers.
- Dosage ranges: Dependent claims can specify a particular daily dosage or frequency of administration.
- Specific pH ranges: Claims may define the pH of the composition more precisely.
These dependent claims offer layered protection, covering specific embodiments of the broader claims.
What is the Patent Landscape Surrounding US 7,173,037?
The patent landscape for a drug includes not only the primary composition and method patents but also related patents covering manufacturing processes, polymorphs, formulations, and new uses.
What are the Key Patents Held by the Assignee?
Jazz Pharmaceuticals holds a portfolio of patents related to GHB, the most prominent being:
- US 7,173,037 B2: The foundational patent for the composition and method of treatment. This patent issued on February 6, 2007.
- US 8,722,014 B2: Titled "Oral Dosage Formulations of Gamma-Hydroxybutyrate," this patent, issued on May 13, 2014, describes specific oral dosage forms of GHB with improved palatability and stability. It often covers specific formulations like taste-masked compositions.
- US 9,427,436 B2: Titled "Gamma-hydroxybutyrate compositions and methods of treatment," this patent, issued on August 30, 2016, appears to cover further refinements in GHB compositions and their therapeutic applications.
These patents, in aggregate, aim to provide a comprehensive intellectual property shield for the drug product.
Are There Any Key Challenges or Litigation Involving This Patent?
Patents for successful drugs are frequently subject to challenges, particularly by generic manufacturers seeking to enter the market. Litigation often centers on:
- Patent Validity: Generic companies may file Paragraph IV certifications under the Hatch-Waxman Act, asserting that the patent is invalid or will not be infringed by their proposed generic product.
- Patent Infringement: The patent holder may sue for infringement if a generic product is deemed to fall within the scope of one or more of its patents.
- Obviousness: A common argument is that the claimed invention would have been obvious to a person of ordinary skill in the art at the time of filing.
- Anticipation: Claims are challenged if they are deemed to have been previously disclosed by prior art.
Jazz Pharmaceuticals' key product utilizing GHB is Xyrem (sodium oxybate). Litigation surrounding Xyrem has involved numerous challenges to its patent portfolio by generic manufacturers. For instance, challenges to patents covering Xyrem have led to significant legal battles and, in some cases, early market entry for generic versions of sodium oxybate, despite the existence of patents like US 7,173,037. The outcome of these challenges depends on the specific claims being litigated and the evidence presented.
What is the Status of Patent Protection (Expiry)?
The term of a U.S. patent is generally 20 years from the date on which the application for the patent was filed. However, patent term extensions (PTE) can be granted to compensate for delays in regulatory review by the U.S. Food and Drug Administration (FDA).
- US 7,173,037 B2: Filed on November 17, 2000, its nominal expiration would be November 17, 2020. However, due to potential patent term extensions, the actual period of protection could be extended. For Xyrem (sodium oxybate), patent term extensions were sought and granted for related patents, pushing the effective market exclusivity beyond the initial 20-year term for certain formulations and indications. Specific expiry dates for patents, especially with extensions, require detailed analysis of USPTO records.
The expiry of primary patents does not always mean the end of market exclusivity, as later-expiring patents covering specific formulations, manufacturing processes, or new indications can extend protection.
Comparative Analysis: US 7,173,037 and Related IP
Understanding the relationship between US 7,173,037 and other intellectual property rights is crucial for a comprehensive analysis.
How does US 7,173,037 Compare to Later Formulation Patents?
US 7,173,037 provides foundational protection for the GHB composition and its use in treating narcolepsy and idiopathic hypersomnia. Later patents, such as US 8,722,014 B2, often focus on specific formulation improvements.
- US 7,173,037: Claims basic GHB compositions with buffering agents and carriers for oral administration.
- US 8,722,014 B2: Focuses on specific characteristics like taste masking, reduced odor, improved stability, and controlled release mechanisms for oral GHB formulations. This patent can provide a distinct layer of protection for the actual marketed product if it embodies these later-developed formulation advantages.
This layered approach allows the patent holder to protect the core invention and subsequent innovations that enhance the drug's usability, efficacy, or manufacturing efficiency.
What is the Impact of Generic Competition on This Patent?
The expiration or successful challenge of patents like US 7,173,037 can significantly impact market exclusivity.
- Post-Expiry: Once the core patents expire and are not extended by PTE, generic manufacturers can seek FDA approval to market their own versions of GHB for the approved indications.
- Litigation Outcomes: Litigation can result in a court finding a patent invalid, not infringed, or unenforceable. This can allow generic entry even before the patent's nominal expiry date. For Xyrem, the patent landscape has been complex, with some patents successfully defended and others subject to successful challenges, leading to periods of uncertainty and market shifts.
The presence of a strong patent portfolio, including foundational patents like US 7,173,037, is intended to deter or delay generic entry. However, the dynamic nature of patent law and pharmaceutical R&D means that such protection is subject to ongoing legal and commercial pressures.
Key Takeaways
Patent US 7,173,037 B2 establishes foundational intellectual property for pharmaceutical compositions containing gamma-hydroxybutyrate (GHB) and methods for treating narcolepsy and idiopathic hypersomnia. Its claims cover specific combinations of GHB, buffering agents, and carriers, alongside therapeutic methods utilizing these compositions. The patent is part of a broader intellectual property strategy by Jazz Pharmaceuticals, Inc., which includes later patents focusing on improved formulations and manufacturing processes. While this patent provided significant initial market exclusivity, its effective protection has been subject to legal challenges and the expiration of its term, impacting the competitive landscape for GHB-based therapies.
Frequently Asked Questions
-
What is the primary indication for which US 7,173,037 claims protection?
US 7,173,037 claims protection for methods of treating idiopathic hypersomnia and narcolepsy.
-
What specific components are required for a pharmaceutical composition to fall under Claim 1 of US 7,173,037?
Claim 1 requires gamma-hydroxybutyrate (GHB), a buffering agent, and a pharmaceutically acceptable carrier.
-
When did US 7,173,037 expire based on its filing date?
Based on its filing date of November 17, 2000, the nominal expiration of US 7,173,037 was November 17, 2020. However, potential Patent Term Extensions (PTE) could have altered the effective protection period.
-
Can generic versions of Xyrem be marketed if US 7,173,037 is still in force?
The ability to market generic versions depends on the status of all relevant patents, including US 7,173,037 and any extensions or related patents, as well as any successful legal challenges or settlement agreements.
-
What is the significance of the "buffering agent" in the claims of US 7,173,037?
The buffering agent is claimed to enhance the stability of the GHB composition, potentially improving its shelf life and therapeutic performance.
Citations
- Jazz Pharmaceuticals, Inc. (2007). U.S. Patent 7,173,037 B2: Pharmaceutical compositions containing gamma-hydroxybutyrate and methods of treatment. United States Patent and Trademark Office.
- Jazz Pharmaceuticals, Inc. (2014). U.S. Patent 8,722,014 B2: Oral dosage formulations of gamma-hydroxybutyrate. United States Patent and Trademark Office.
- Jazz Pharmaceuticals, Inc. (2016). U.S. Patent 9,427,436 B2: Gamma-hydroxybutyrate compositions and methods of treatment. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
